Abstract:Introduction: The ataxia-telangiectasia and Rad3-related (ATR) protein kinase is an attractive target for cancer therapies as it is an apical initiator of DNA damage response (DDR) pathways that facilitate cell cycle arrest and DNA repair, thus promoting survival of cancer cells. Several ATR inhibitors (ATRi) are in clinical development including berzosertib (M6620, VX-970), which is currently being evaluated in combination with cytotoxic chemotherapies and radiation. Although clinical studies have examined plasma pharmacokinetics (PK) in humans, little is known regarding dose/exposure relationships and tissue distribution which may influence berzosertib's therapeutic window. To understand these concepts, we extensively described the PK of berzosertib in mouse plasma and tissue. Methods: Dose proportionality was assessed using single IV doses of berzosertib (2, 6, 20 and 60 mg/kg) administered to female BALB/c mice. Mice were euthanized from 5 min to 24 h post-dose. Using a highly sensitive LC-MS/MS method, berzosertib was quantitated in red blood cells, plasma, and tissues. Non-compartmental analysis (NCA) was performed using Phoenix WinNonlin to determine relevant PK parameters. Dose linearity was assessed by statistical comparison of dose-normalized plasma Cmax and dose-normalized tissue AUC across the four dose levels. Statistical analyses were performed using ANOVA with Tukey's multiple comparisons test. Berzosertib plasma protein binding was assessed in vitro from 300 ng/mL to 100 μg/mL using rapid equilibrium dialysis. An extensive PK study was also conducted in tumor-bearing mice to assess distribution by quantitating drug in tissues. Results: The dose proportionality study indicated that both plasma Cmax and AUC increase with dose, and dose-normalized concentration vs time profiles suggested nonlinear increases in exposure based on different terminal slopes. At the two highest doses, dose-normalized AUC in each tissue were greater than the exposure generated at the two lowest doses. However, log transformations of AUC0-360 plotted vs dose generated a slope of 0.886 (95% CI: 0.718 - 1.054), suggesting a linear relationship. The fraction of unbound berzosertib in mouse plasma increased at concentrations above 10 μg/mL, which is a concentration exceeded at the two highest doses and where nonlinearity in exposure is observed. Tissue analysis revealed the following tissues had a tissue/plasma coefficient >1: bone marrow, kidney, liver, spleen, lung, tumor, lymph nodes, thymus, and heart. Conclusion: IV berzosertib displayed nonlinear PK in mice. Increased doses of berzosertib were associated with greater than proportional increases in plasma and tissue exposure most likely due to saturation of plasma protein binding. Our results will help to understand preclinical pharmacodynamic and toxicity data and subsequent PBPK modeling to inform optimal dosing and clinical deployment of berzosertib. Citation Format: Joshua J. Deppas, Brian F. Kiesel, Jianxia Guo, Robert A. Parise, Christopher J. Bakkenist, Jan H. Beumer. Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7171.

Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice

Abstract 7171: Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration

Abstract CT272: Pharmacodynamic and immunophenotyping analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

1666Tip Phase II Study of Berzosertib (M6620) + Topotecan in Patients with Relapsed Platinum-Resistant SCLC: DDRiver SCLC 250

The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer

ATR inhibition radiosensitizes cells through augmented DNA Damage and G2 cell cycle arrest abrogation

Targeting ATR Kinase as a Strategy for Canine Lymphoma and Leukaemia Treatment

An Open-Label, Single-Arm, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Inhibitor SC0245 in Advanced Solid Malignancies.

Abstract 312: The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons

Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo

Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors

Abstract 7127: An ATM inhibitor: ZN-B-2262 in combination with radiation/ADCs containing topoisomerase inhibitors for the treatment of solid tumors

Abstract CT196: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors

Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers